%PDF-1.4
%
46 0 obj
<>
endobj
43 0 obj
<>
endobj
111 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2005-01-10T11:12:52Z
2024-03-29T00:14:05-07:00
QuarkXPressª: AdobePS 8.8.0 (301)
2024-03-29T00:14:05-07:00
application/pdf
Heather
2003-953.feb
uuid:9d5cf9fd-1dd1-11b2-0a00-3208278d5b00
uuid:9d5cfa00-1dd1-11b2-0a00-1e0000000000
endstream
endobj
32 0 obj
<>
endobj
33 0 obj
<>
endobj
47 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 16 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 18 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 20 0 R/Type/Page>>
endobj
7 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 22 0 R/Type/Page>>
endobj
10 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 24 0 R/Type/Page>>
endobj
13 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 26 0 R/Type/Page>>
endobj
133 0 obj
[137 0 R]
endobj
134 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
13.5 787.5 585 -783 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 72 736.1941 Tm
(polymorphism related to joint damage in rheumatoid arthritis. Mol)Tj
0 Tc 0 -1.25 TD
(Med 1998;4:724-33.)Tj
-0.00011 Tc -1.7885 -1.25 Td
[(33.)-538.6 (W)39.8 (ilson )54.8 (AG, Gordon C, di Giovine FS, et al. )54.8 (A)-220.1 (genetic association)]TJ
1.7885 -1.25 Td
(between systemic lupus erythematosus and tumor necrosis factor)Tj
T*
(alpha. Eur J Immunol 1994;24:191-5.)Tj
-1.7885 -1.25 Td
[(34.)-538.6 (Rudwaleit M, )17.7 (T)35 (ikly M, Khamashta M, et al. Interethnic dif)17.7 (ferences)]TJ
1.7885 -1.25 Td
(in the association of tumor necrosis factor promoter polymorphisms)Tj
T*
(with systemic lupus erythematosus. J Rheumatol 1996;23:1725-8.)Tj
-1.7885 -1.25 Td
[(35.)-538.6 (Rood MJ, van Krugten MV)128.8 (, Zanelli E, et al. )17.7 (TNF-308A)-220.2 (and )]TJ
1.7885 -1.25 Td
(HLA-DR3 alleles contribute independently to susceptibility to )Tj
T*
[(systemic lupus erythematosus. )54.8 (Arthritis Rheum 2000;43:129-34.)]TJ
-1.7885 -1.25 Td
[(36.)-538.6 (V)110.8 (an der Linden MW)91.7 (, van der Slik )54.8 (AR, Zanelli E, et al. Six)]TJ
1.7885 -1.25 Td
(microsatellite markers on the short arm of chromosome 6 in relation)Tj
T*
[(to HLA-DR3 and )17.7 (TNF-308A)-220.2 (in systemic lupus erythematosus.)]TJ
T*
(Genes Immun 2001;2:373-80.)Tj
-1.7885 -1.25 Td
[(37.)-538.6 (Zuniga J, )17.7 (V)110.8 (a)0.3 (r)17.7 (gas-Alarc\227n G, Hernandez-Pacheco G, Portal-Celhay)]TJ
1.7885 -1.25 Td
[(C, )36.8 (Y)99.8 (amamoto-Furusho JK, Granados J. )17.7 (T)35 (umor necrosis factor)19.7 (-alpha)]TJ
T*
(promoter polymorphisms in Mexican patients with systemic lupus)Tj
T*
(erythematosus. Genes Immun 2001;2:363-6.)Tj
-1.7885 -1.25 Td
[(38.)-538.6 (T)69.9 (suchiya N, Kawasaki )54.8 (A, )17.7 (T)69.9 (sao BP)110.7 (, Komata )17.7 (T)74 (, Grossman JM,)]TJ
1.7885 -1.25 Td
[(T)69.9 (okunaga K. )54.8 (Analysis of the association of HLA-DRB1, )17.7 (TNF alpha)]TJ
T*
[(promoter and )17.7 (TNFR2 \(TNFRSF1B\) polymorphisms with SLE using)]TJ
T*
(transmission disequilibrium test. Genes Immun 2001;2:317-22.)Tj
-1.7885 -1.25 Td
[(39.)-538.6 (D\325Alfonso S, Colombo G, Della Bella S, Scorza R, )]TJ
1.7885 -1.25 Td
[(Momigliano-Richiardi P)110.7 (.)-0.1 ( )54.8 (Association between polymorphisms in the)]TJ
T*
(TNF region and systemic lupus erythematosus in the Italian )Tj
0.00729 Tw T*
[(population. T)35 (issue )37.1 (Antigens )-17.7 (1996;47:551-5.)]TJ
0.02499 Tw -1.7885 -1.25 Td
[(40.)-538.6 (Azuma M, Motegi K, )54.8 (Aota K, Hayashi )36.8 (Y)128.9 (, Sato M. Role of cytokines)]TJ
1.7885 -1.25 Td
[(in the destruction of acinar structure in Sj\232gren\325)54.8 (s syndrome salivary)]TJ
T*
(glands. Lab Invest 1997;77:269-80.)Tj
31.2115 36.25 Td
[(41.)-538.6 (Anaya)-275.1 (JM, )17.7 (T)69.9 (alal N. Sj\232gren\325)54.8 (s syndrome comes of age. Semin)]TJ
1.7886 -1.25 Td
(Arthritis Rheum 1999;28:355-9.)Tj
-1.7886 -1.25 Td
[(42.)-538.6 (Heward J, Gough SCL. Genetic susceptibility to the development of)]TJ
1.7886 -1.25 Td
(autoimmune disease. Clin Sci 1997;93:479\32091.)Tj
-1.7886 -1.25 Td
[(43.)-538.6 (Becker KG, Simon RM, Bailey-W)39.7 (ilson JE, et al. Clustering of )]TJ
1.7886 -1.25 Td
(non-major histocompatibility complex susceptibility candidate loci)Tj
T*
[(in human autoimmune diseases. Proc Natl )54.8 (Acad Sci USA)]TJ
0 Tc 0 Tw T*
(1998;95:9979-84.)Tj
-0.00011 Tc 0.02499 Tw -1.7886 -1.25 Td
[(44.)-538.6 (Becker KG. )17.7 (The common variants/multiple disease hypothesis of)]TJ
1.7886 -1.25 Td
(common complex genetic disorders. Med Hypotheses )Tj
0 Tc 0 Tw T*
(2004;62:309-17.)Tj
-0.00011 Tc 0.02499 Tw -1.7886 -1.25 Td
[(45.)-538.6 (T)69.9 (obon G, Correa P)91.7 (A, Gomez LM, Pineda-T)69.7 (amayo, )54.8 (Anaya JM. Lack)]TJ
1.7886 -1.25 Td
[(of association between )17.7 (TNF alpha -308 polymorphism and clinical)]TJ
T*
(and immunological characteristics of systemic lupus erythematosus)Tj
T*
[(and primary Sj\232gren\325)54.8 (s syndrome [abstract]. )54.8 (Ann Rheum Dis)]TJ
0 Tc T*
(2004;63 Suppl:237.)Tj
-0.00011 Tc -1.7886 -1.25 Td
[(46.)-538.6 (Selvaraj P)110.7 (, Sriram U, Mathan Kurian S, Reetha )54.8 (AM, Narayanan PR.)]TJ
1.7886 -1.25 Td
[(T)35 (umor necrosis factor )]TJ
/T1_1 1 Tf
0 Tc 0 Tw [-0.1 (\002)]TJ
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 10.0246 0 Td
(\(-238 and -308\) and \247 gene polymorphisms)Tj
-10.0246 -1.25 Td
(in pulmonary tuberculosis: haplotype analysis with HLA-A, B and)Tj
T*
[(DR genes. )17.8 (T)35 (uberculosis 2001;81:335\32041.)]TJ
-1.7886 -1.25 Td
[(47.)-538.6 (Delgado JC, Baena )54.8 (A, )17.7 (Thim S, Goldfeld )54.8 (AE. Ethnic-specific genetic)]TJ
1.7886 -1.25 Td
(associations with pulmonary tuberculosis. J Infect Dis)Tj
0 Tc 0 Tw T*
(2002;186:1463-8.)Tj
-0.00011 Tc 0.02499 Tw -1.7886 -1.25 Td
[(48.)-538.6 (Mugnier B, Balandraud N, Darque )54.8 (A, Roudier C, Roudier J,)]TJ
1.7886 -1.25 Td
(Reviron D. Polymorphism at position -308 of the tumor necrosis)Tj
T*
(factor alpha gene influences outcome of infliximab therapy in)Tj
T*
[(rheumatoid arthritis. )54.8 (Arthritis Rheum 2003;48:1849-52.)]TJ
-1.7886 -1.25 Td
[(49.)-538.6 (Padyukov L, Lampa J, Heimbur)17.7 (ger M, et al. Genetic markers for the)]TJ
1.7886 -1.25 Td
[(ef)17.7 (ficacy of tumor necrosis factor blocking therapy in rheumatoid)]TJ
0 Tc T*
[(arthritis. )54.9 (Ann Rheum Dis 2003;62: 526-9.)]TJ
ET
0 0 0 1 K
53.964 76.5 m
558.972 76.5 l
S
0 0 0 0 k
52.822 69.665 64.178 -15.665 re
f*
BT
0 0 0 1 k
/T1_2 1 Tf
0 Tw 8 0 0 8 53.8216 56.7343 Tm
(224)Tj
ET
0 0 0 0 k
356 69.665 203 -15.665 re
f*
BT
0 0 0 1 k
/T1_2 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 424.3613 56.7343 Tm
(The Journal of Rheumatology 2005; 32:2)Tj
ET
0 0 0 0 k
/GS0 gs
103.631 81.583 407.5 -10.833 re
f*
0.5 w
/GS1 gs
103.631 81.583 407.5 -10.833 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_3 8 Tf
106.328 74 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2005. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_4 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
26 0 obj
<>stream
8;Z\7$$*pK#ikq,j?&oS5nYec[u!27Bi/s$1"NW3jMZK9[p\N1lTGb"a,e.5h"&+s
2:bY/p1l82Ml:#ed@Uq.,`inF:G^EVl#Z,+@4R,SKWB)i_t-K]fVU@,L58%O7jWA_@!tN7>'nfcf(j6q+@8#=A.O4l-KZ0/R*/"3lRtZ>?7YYB0ikOE>7hK?\Gd]$=qDg)a!AceQUh
AHaU>l76?T9q$gH'in4&DjZK$2sX[+LHgUS=XB9^e4O]EOj9peVho%P::3!;7E;$"
!7r-9lZA@t#=Xf*GSc7MX,3@OV9iqU`H>9ORCqL(_$Belj7K2SmME*o(&EL
AEu1Wi>:igd,SU9%
endstream
endobj
30 0 obj
[/Indexed/DeviceRGB 255 29 0 R]
endobj
29 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
55 0 obj
<>
endobj
50 0 obj
<>
endobj
51 0 obj
<>
endobj
98 0 obj
<>
endobj
116 0 obj
<>
endobj
49 0 obj
<>
endobj
91 0 obj
<>stream
H{PSrC@]WGEDvEvuy"B$@@@$<(
*XDծ2U=QNΙΙ~s98fj8ng`a@n yq'Yf8RS繈(K5EKSmE?4#[|PK3]Z7:9`$ZNopsw!JqRzu̯
>YN7XQID +)F$NRAMoOHJh@"oL%4D-&dݗ'ŮiN-
b@seÍ31+zۀaM-97Va1laqVckފdcrp *1SiMfdm5;[W[p,|,4EF,-Vl2ifN6ŏYWkm[lBYQ{?\%eU<./*o7Ish0h,hh*hS7ÆցKJKmoSu"Qjș7xC